Denali Therapeutics (DNLI) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...
Denali Therapeutics price target lowered to $28 from $30 at BofA
BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...
Proficio Capital Partners LLC Acquires New Shares in Denali Therapeutics Inc. (NASDAQ:DNLI)
Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...
Morgan Stanley Begins Coverage on Denali Therapeutics (NASDAQ:DNLI)
Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...
pharmaphorum3d
Denali's ALS programme suffers another setback
Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
Endpoints News4d
De­nali stops some work on ALS drug af­ter analy­sis showed no im­pact on key bio­mark­er
Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for ...
Fierce Biotech4d
Denali's ALS drug fails to redeem itself, missing key biomarker in trial extension
Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...